FDA Approves Brepocitinib as First Oral Drug for Dermatomyositis

The FDA approved brepocitinib as the first oral targeted therapy for adult dermatomyositis, supported by phase 3 trial data demonstrating substantial improvement in muscle, skin, and overall disease symptoms with reduced steroid dependence.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 27 Aug 2026 and 28 Aug 2026.